46. Malignant rheumatoid arthritis Clinical trials / Disease details

Clinical trials : 4,325 / Drugs : 2,671 - (DrugBank : 417) / Drug target genes : 187 - Drug target pathways : 224

2 trials found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT01001832 (ClinicalTrials.gov)	December 2009	26/10/2009	Efficacy, Pharmacokinetics, Safety, and Immunogenicity Study of Abatacept Administered Subcutaneously to Treat Rheumatoid Arthritis in Japanese Patients	A Phase II/III, Multicenter, Randomized, Double-Blind, Double-Dummy Study to Assess Similarity of the Efficacy, Pharmacokinetics, Safety and Immunogenicity of Abatacept Administered Subcutaneously or Intravenously in Japanese Subjects With Rheumatoid Arthritis, Receiving Background Methotrexate, and Experiencing an Inadequate Response to Methotrexate	Rheumatoid Arthritis	Drug: Intravenous (IV) abatacept;Drug: Subcutaneous (SC) abatacept	Bristol-Myers Squibb	NULL	Completed	20 Years	N/A	All	118	Phase 2/Phase 3	Japan
2	NCT00559585 (ClinicalTrials.gov)	January 2008	15/11/2007	Methotrexate-Inadequate Response Study	A Phase IIIB Multicenter, Randomized, Double-Blind, Double-Dummy Study to Compare the Efficacy and Safety of Abatacept Administered Subcutaneously and Intravenously in Subjects With Rheumatoid Arthritis, Receiving Background Methotrexate, and Experiencing an Inadequate Response to Methotrexate	Rheumatoid Arthritis (RA)	Drug: Subcutaneous (SC) Abatacept;Drug: Intravenous (IV) Abatacept	Bristol-Myers Squibb	NULL	Completed	18 Years	N/A	All	2492	Phase 3	United States;Argentina;Australia;Belgium;Brazil;Canada;France;Germany;Greece;Hungary;India;Ireland;Italy;Korea, Republic of;Mexico;Netherlands;Peru;Poland;Russian Federation;South Africa;Taiwan;Turkey;United Kingdom;Austria;Spain;Chile